Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study (Q44130928)
Jump to navigation
Jump to search
scientific article published on 6 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study |
scientific article published on 6 September 2014 |
Statements
1 reference
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study (English)
1 reference
Maria Rachele Bianchi
6 September 2014
1 reference